Using Pegylated Liposomal Doxorubicin for Metastatic Breast Cancer
Author Information
Author(s): Fiegl Michael, Mlineritsch Brigitte, Hubalek Michael, Bartsch Rupert, Pluschnig Ursula, Steger Günther G
Primary Institution: Medical University of Innsbruck
Hypothesis
Can pegylated liposomal doxorubicin (PLD) be an effective treatment for heavily pretreated metastatic breast cancer patients?
Conclusion
PLD is a valuable treatment option for advanced breast cancer, even in patients who have undergone multiple prior therapies.
Supporting Evidence
- Response rate was 26%, with stable disease in 19% of patients.
- Median progression-free survival was 5.8 months and overall survival was 14.2 months.
- Most common side effects included palmar-plantar erythrodysesthesia (17%) and exanthema (14%).
Takeaway
This study shows that a special cancer medicine called PLD can help people with advanced breast cancer feel better and live longer, even if they have already tried other treatments.
Methodology
129 patients with advanced breast cancer received PLD as monotherapy, and their responses and side effects were documented.
Potential Biases
Patients included had various prior treatments and comorbidities, which may introduce bias in treatment outcomes.
Limitations
The study was observational and did not require formal ethical approval, which may affect the generalizability of the results.
Participant Demographics
Median age was 63 years, with most patients having multiple cardiac risk factors.
Statistical Information
P-Value
0.010
Confidence Interval
95%CI, 1.05-2.61
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website